Product Information
AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT is a brand product labeled by Mannkind Corporation, priced at $7.7805 per EA under NDC 47918088018. Its NADAC has been published 120 times since Jun 19, 2024.
Manufacturer
Mannkind CorporationNDC
47918088018
Classification
Brand
Dosage Form
KIT
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA022472On Market Since
7/1/2016
Price Statistics
The NADAC for AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT has been published 120 times since Jun 19, 2024, and over the history we have for it it has risen 7.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.7805 per EA |
|---|---|
| All-time high | $7.8585 (Sep 16, 2026) |
| All-time low | $7.2217 (Jun 19, 2024) |
| 52-week high | $7.8585 |
| 52-week low | $7.6113 |
| Median price | $7.5895 |
| Average price | $7.5823 |
| Largest weekly change | +5.0% (Dec 18, 2024) |
| Weeks tracked | 120 |
| Tracking since | Jun 19, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mannkind Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
INSULIN HUMAN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT?
The current National Average Drug Acquisition Cost (NADAC) for AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT, manufactured by Mannkind Corporation, is $7.7805 per EA (NDC 47918088018), effective Sep 30, 2026.
How has the price of AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT changed over time?
Over the history we have for it, the NADAC for AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT has risen 7.7%. It has been tracked across 120 weekly CMS publications since Jun 19, 2024.
What are the highest and lowest recorded NADAC prices for AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT?
Since Jun 19, 2024, the NADAC for AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT has ranged from a low of $7.2217 (Jun 19, 2024) to a high of $7.8585 (Sep 16, 2026), with a median of $7.5895 per EA.
Are there cheaper alternatives to AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT in a comparable dosage form, but none are currently priced below it.
Who manufactures AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT?
AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT (NDC 47918088018) is labeled by Mannkind Corporation, and CMS classifies it as a brand product.